PharmaResearch Co., Ltd.
214450.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.14T
Close$
Share Statistics
| Market cap | $3.14 Trillion |
|---|---|
| Enterprise Value | $3.14 Trillion |
| Dividend Yield | $1100.00 (0.36%) |
| Earnings per Share | $15893 |
| Beta | 0.44 |
| Outstanding Shares | 10,327,000 |
Return
| Return on Equity | 24.64% |
|---|---|
| Return on Assets | 16.77% |
| Return on Invested Capital | 17.96% |
Valuation & Multiples
| P/E Ratio | 16.93 |
|---|---|
| PEG | 87.51 |
| Price to Sales | 4.68 |
| Price to Book Ratio | 3.57 |
| Enterprise Value to Revenue | 5.21 |
| Enterprise Value to EBIT | 17.41 |
| Enterprise Value to Net Income | 16 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.29 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 7, 2026
EPS Estimate
$4043.92
Average shareholder expectationRevenue Estimate
$174.64 B
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$3355.05
Average shareholder expectationRevenue Estimate
$180.81 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About PharmaResearch Co., Ltd.
526 employees
CEO: Jung Sang-soo PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injec...